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124 Eradication of Pseudomonas aeruginosa in children with cystic
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Melbourne, Parkville, Australia; 2Royal Children’s Hospital, Parkville, Australia;
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Introduction: Early eradication therapy for Pseudomonas aeruginosa (Pa) reduces
morbidity and mortality in cystic ﬁbrosis (CF) lung disease. Standard Pa eradication
at Royal Children’s Hospital (RCH) is 3 months inhaled tobramycin and oral
ciproﬂoxacin in months 1 and 3. A preceding two weeks of IV antibiotics are
given to children <6 years of age or those clinically unwell.
Objective: The aim of this study was to evaluate success of Pa eradication using
two deﬁnitions.
Methods: A retrospective review of eradication success in children acquiring Pa
between August 2004 and August 2011 was conducted. Pa eradication at RCH was
deﬁned by
1. no Pa on three specimens (sputum or oropharyngeal) obtained at least one month
apart after end of treatment; or
2. no Pa on BAL and another specimen (BAL, sputum or oropharyngeal) obtained
at least one month apart after end of treatment.
Absence of Pa in a single specimen obtained 1 month after end of treatment
period was also examined for comparison (“single specimen deﬁnition”).
Results: 101 episodes of Pa eradication were reviewed in 57 CF patients (61.4%
male). Median age at start of eradication was 7.9 years (range 0.3–17.6 years).
Table 1. Success of Pa eradication at RCH
Successful eradication
No. of
patients
RCH deﬁnition,
n (%)
Single specimen
deﬁnition, n (%)
Two-tailed p value
(Fisher’s exact test)
1st eradication 57 41 (71.9) 47 (82.5) 0.26
2nd eradication 28 17 (60.7) 19 (67.9) 0.78
3rd eradication 16 8 (50.0) 12 (75.0) 0.27
Conclusion: We report rates of Pa clearance lower than those observed in previous
studies. However, deﬁning “eradication” by a single culture result may overestimate
treatment success. Our study highlights the need to develop and adopt a standardised
and stringent deﬁnition for Pa eradication.
125 Presence of Pandoraea and Herbaspirillum species within the
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Objective: To provide molecular characterization of Pandoraea and Herbaspirillum
strains isolated from Irish CF patients.
Materials and Methods: Molecular analysis using the 16S rRNA gene, gyrB gene
and rpoB gene in addition to MALDI-TOF MS was used for species characterisa-
tion. Clonality was assessed using PFGE and BOX-PCR and the presence of class 1
integrons were also investigated.
Results: Over a study period of 6 years 11 Pandoraea positive patients and
12 Herbaspirillum positive patients were identiﬁed. 16S rRNA gene sequencing
conﬁrmed Pandoraea species to be P. pnomenusa (5 patients), P. pulmonicola (3 pa-
tients) and 3 patients isolating an as yet unclassiﬁed Pandoraea sp. Clonal analysis
revealed the capacity of P. pnomenusa and P. pulmonicola to be transmissible from
patient to patient. Class 1 integrons containing antibiotic resistance genes were also
found which may have contributed to pan-resistance in strains.
Herbaspirillum species were conﬁrmed as H. huttensie subsp. putei by DNA
sequencing and were shown to be part of an incident of transmission among CF
and non CF patients.
Conclusion: These reported cases of infection indicate species of Pandoraea and
Herbaspirillum are present in the Irish CF population. While Pandoraea species
have been shown to possess signiﬁcant capacity to elicit pro inﬂammatory response
in CF lung cells Herbaspirillum species while potentially transmissible have yet to
be evaluated for pathogenic impact.
126 Typing of Prevotella spp. from CF and patients with other
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Objectives: Anaerobic bacteria from a range of genera have been detected in large
numbers in sputum from CF patients with Prevotella spp. frequently isolated.
Prevotella are well known oral pathogens and considered signiﬁcant in other
polymicrobial lung infections. This study aimed to determine whether any species
of Prevotella are particularly associated with colonisation of the respiratory tract.
Methods: Prevotella isolates from CF sputum (n = 52), non-CF clinical isolates
from a range of body sites (n = 57; of which n = 7 respiratory and n = 50 non-
respiratory) and type strains (n = 5) were cultured under strict anaerobic conditions.
Isolates were typed by 16s rDNA sequencing, Pulse Field Gel Electrophoresis
(PFGE) and Random Ampliﬁcation of Polymorphic DNA (RAPD).
Results: 16s rDNA sequencing data grouped isolates (n = 101) into clusters (n = 17)
dependent upon species. In contrast, dendrograms produced by analysis of both
PFGE (n = 95) and RAPD (n = 103) grouped isolates into clusters (n = 11 and 12,
respectively) which contained different Prevotella species. Also, the same species
appeared in more than one cluster. There was no trend as to the clustering of isolates
from either condition (CF vs non-CF) or source (respiratory vs non-respiratory).
Conclusion: The methods used in this study have shown that no particular
Prevotella species were particularly associated with colonisation of the respiratory
tract in either CF or non-CF patients. Both PFGE and RAPD indicated a signiﬁcant
degree of homology between Prevotella isolates, which were identiﬁed as distinct
species by 16s rDNA sequencing. This may suggest limitations to 16s rDNA
sequencing for deﬁnitive identiﬁcation and speciation of Prevotella.
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Aim: To determine the prevalence and clinical signiﬁcance of B. petrii in cystic
ﬁbrosis (CF) patients.
Method: Four patients in the Midwest (MW) of Ireland yielded Bordetella species
from clinical specimens, these isolates were sent to a reference lab for speciation.
Identiﬁcation was determined by 16s RNA sequencing of a 1407 bp region and
MALDI-TOF analysis. Strain relatedness was determined by BOX AIR PCR
and Pulsed Field Gel Electrophoresis (PFGE). A follow-up prevalence study was
performed anonymously on archived DNA from CF sputae in the Reference Lab
contributed by several other CF centres in Ireland using 16s RNA sequencing of
105 CF sputum samples. A retrospective epidemiological investigation of the MW
cluster was also undertaken.
Results: Six of 105 were positive for B. petrii in the prevalence study which had
not been detected by standard culture techniques. All MW isolates were indistin-
guishable by the above methods. The MW patients were clustered geographically in
the same county of Ireland and were all chronically colonised with Pseudomonas
aeruginosa. The ﬁrst report of B. petrii isolation in the group was in 2009, with all
other isolates occurring in 2010/11. All patients had differing baselines of physical
condition and were therefore compared through various methods such as FEV1
trends, Quality of Life Scores, etc. The clinical signiﬁcance of B. petrii was assessed
by detailing symptoms at the time of positive sputum result, the presence/absence
of co-pathogens on sputum culture and antimicrobial sensitivity of B. petrii to the
antibiotic regime used.
Conclusion: These ﬁndings suggest that this bacterium may be underreported in
the CF population.
